Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Gerardus WJ Frederix & Renske MT ten Ham. (2023) Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step. Expert Review of Pharmacoeconomics & Outcomes Research 23:8, pages 853-856.
Read now
Read now
Olga Pitsillidou, Panagiotis Petrou & M. J. Postma. (2023) Implementing a Managed Entry Agreement Framework in Cyprus. Expert Review of Pharmacoeconomics & Outcomes Research 23:8, pages 857-865.
Read now
Read now
Jesper Jørgensen, Eve Hanna & Panos Kefalas. (2020) Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. Journal of Market Access & Health Policy 8:1.
Read now
Read now
Jesper Jørgensen & Panos Kefalas. (2019) Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Jesper Jørgensen, Spiros Servos & Panos Kefalas. (2018) The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Articles from other publishers (23)
Michelle A. Farrar, Loudella Calotes-Castillo, Ranil De Silva, Peter Barclay, Lani Attwood, Julie Cini, Monica Ferrie & Didu S. Kariyawasam. (2023) Gene therapy-based strategies for spinal muscular atrophy—an Asia-Pacific perspective. Molecular and Cellular Pediatrics 10:1.
Crossref
Crossref
Rositsa Koleva-Kolarova, László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Balázs Nagy, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mölken, Sarah Wordsworth & Apostolos Tsiachristas. (2023) Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Personalized Medicine.
Crossref
Crossref
Conor Hennessy, Milena Deptula, Joanna Hester & Fadi Issa. (2023) Barriers to Treg therapy in Europe: From production to regulation. Frontiers in Medicine 10.
Crossref
Crossref
Verlumun Celestine Gever, Timothy Onosahwo Iyendo, Udoka O. Obiugo-Muoh, Joshua Kayode Okunade, Ngozi Agujiobi-Odoh, Ngozi Udengwu, Felix Olajide Talabi & Peter N. Nwokolo. (2023) Comparing the effect of social media-based drama, music and art therapies on reduction in post-traumatic symptoms among Nigerian refugees of Russia's invasion of Ukraine. Journal of Pediatric Nursing 68, pages e96-e102.
Crossref
Crossref
Zornitsa Mitkova, Maria Dimitrova, Miglena Doneva, Konstantin Tachkov, Maria Kamusheva, Lyubomir Marinov, Nikolay Gerasimov, Dimitar Tcharaktchiev & Guenka Petrova. (2022) Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria. Frontiers in Public Health 10.
Crossref
Crossref
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A. Vreman, Johan Pontén, Tea Strbad, Dalia Dawoud, Alexander Kostyuk, Ahmed Seyam, László Nagy, Wim G. Goettsch & Zoltán Kaló. (2022) Delayed payment schemes in Central-Eastern Europe and Middle-East. Frontiers in Medicine 9.
Crossref
Crossref
Rositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth & Apostolos Tsiachristas. (2022) Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. Applied Health Economics and Health Policy 20:4, pages 501-524.
Crossref
Crossref
Axel Böhnke, Christof Minartz, Sabine Radeck-Knorre, Carsten Schwenke & Aljoscha S Neubauer. (2021) Gentherapie für seltene Erkrankungen: Unterschiede zu chronischer Therapie und Beispiel AADC-Mangel. Gesundheitsökonomie & Qualitätsmanagement 27:01, pages 25-35.
Crossref
Crossref
Patricia Vella Bonanno, Vincent Cassar & Brian Godman. (2021) A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges. Frontiers in Pharmacology 12.
Crossref
Crossref
Genevieve Shemie, Minh Thu Nguyen, John Wallenburg, Felix Ratjen & Bartha Maria Knoppers. (2021) The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. Journal of Personalized Medicine 11:5, pages 382.
Crossref
Crossref
Jesper Jørgensen & Panos Kefalas. (2021) The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regenerative Medicine 16:4, pages 405-422.
Crossref
Crossref
Neil Stephens, Michael Morrison, Paul Martin & Linda Hogle. (2021) Spatiotemporal readiness is key to preparing regenerative medicine for the clinic. Regenerative Medicine 16:3, pages 229-235.
Crossref
Crossref
Marta Carvalho, Bruno Sepodes & Ana Paula Martins. (2021) Patient access to gene therapy medicinal products: a comprehensive review. BMJ Innovations 7:1, pages 123-134.
Crossref
Crossref
Sissel Michelsen, Salma Nachi, Walter Van Dyck, Steven Simoens & Isabelle Huys. (2020) Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. Frontiers in Pharmacology 11.
Crossref
Crossref
Doug Coyle, Isabelle Durand-Zaleski, Jasmine Farrington, Louis Garrison, Johann-Matthias Graf von der Schulenburg, Wolfgang Greiner, Louise Longworth, Aurélie Meunier, Anne-Sophie Moutié, Stephen Palmer, Zack Pemberton-Whiteley, Mark Ratcliffe, Jie Shen, Doug Sproule, Kun Zhao & Koonal Shah. (2020) HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European Journal of Health Economics 21:9, pages 1421-1437.
Crossref
Crossref
Rick A Vreman, Thomas F Broekhoff, Hubert GM Leufkens, Aukje K Mantel-Teeuwisse & Wim G Goettsch. (2020) Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. International Journal of Environmental Research and Public Health 17:22, pages 8309.
Crossref
Crossref
Wendy White. (2019) A rare disease patient/caregiver perspective on fair pricing and access to gene-based therapies. Gene Therapy 27:10-11, pages 474-481.
Crossref
Crossref
Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Maurílio Souza Cazarim, Laís Lessa Neiva Pantuzza, Nelio Gomes Ribeiro-Junior, André Luiz Pereira, Marcus Carvalho Borin, Isabella de Figueiredo Zuppo, Roberto Iunes, Tomas Pippo, Renata Curi Hauegen, Carlos Vassalo, Tracey-Lea Laba, Steven Simoens, Sergio Márquez, Carolina Gomez, Luka Voncina, Gisbert W. Selke, Livio Garattini, Hye-Young Kwon, Jolanta Gulbinovic, Aneta Lipinska, Maciej Pomorski, Lindsay McClure, Jurij Fürst, Rosana Gambogi, Carla Hernandez Ortiz, Vânia Cristina Canuto Santos, Denizar Vianna Araújo, Vânia Eloisa Araujo, Francisco de Assis Acurcio, Juliana Alvares-Teodoro & Augusto Afonso Guerra-Junior. (2020) Integrative Review of Managed Entry Agreements: Chances and Limitations. PharmacoEconomics 38:11, pages 1165-1185.
Crossref
Crossref
Monique Dabbous, Lylia Chachoua, Aleksandra Caban & Mondher Toumi. (2020) Managed Entry Agreements: Policy Analysis From the European Perspective. Value in Health 23:4, pages 425-433.
Crossref
Crossref
Daryl S. Spinner, Moira Ringo & Eric Faulkner. 2020. Second Generation Cell and Gene-based Therapies. Second Generation Cell and Gene-based Therapies
705
745
.
Daryl S. Spinner, Eric C. Faulkner, Marissa C. Carroll, Moira C. Ringo & John W. Joines. (2019) Regenerative Medicine and Cell Therapy in Orthopedics—Health Policy, Regulatory and Clinical Development, and Market Access. Techniques in Orthopaedics 34:4, pages 224-243.
Crossref
Crossref
Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C. Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P. Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso GuerraJr.Jr., Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O. Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C. Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell & Alan Haycox. (2018) Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health 6.
Crossref
Crossref
Renske M.T. ten Ham, Jarno Hoekman, Anke M. Hövels, Andre W. Broekmans, Hubert G.M. Leufkens & Olaf H. Klungel. (2018) Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. Molecular Therapy - Methods & Clinical Development 11, pages 121-130.
Crossref
Crossref